NeoGenomics Inc (NEO) - Total Liabilities
Based on the latest financial reports, NeoGenomics Inc (NEO) has total liabilities worth $565.65 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore NeoGenomics Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
NeoGenomics Inc - Total Liabilities Trend (2000–2025)
This chart illustrates how NeoGenomics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see NeoGenomics Inc balance sheet assets.
NeoGenomics Inc Competitors by Total Liabilities
The table below lists competitors of NeoGenomics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shandong Linglong Tyre Co Ltd
SHG:601966
|
China | CN¥23.32 Billion |
|
NIB Holdings Ltd
AU:NHF
|
Australia | AU$992.90 Million |
|
Klaviyo, Inc.
NYSE:KVYO
|
USA | $417.14 Million |
|
Metcash Ltd
AU:MTS
|
Australia | AU$5.51 Billion |
|
Boyd Group Services Inc.
NYSE:BGSI
|
USA | $2.14 Billion |
|
XiAn Shaangu Power Co Ltd
SHG:601369
|
China | CN¥15.20 Billion |
|
Trinity Industries Inc
NYSE:TRN
|
USA | $7.09 Billion |
|
OPERAD.D.SIT.MEX.A1 -01
F:98Y
|
Germany | €60.76 Billion |
Liability Composition Analysis (2000–2025)
This chart breaks down NeoGenomics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of NeoGenomics Inc to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.72 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.42 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NeoGenomics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NeoGenomics Inc (2000–2025)
The table below shows the annual total liabilities of NeoGenomics Inc from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $523.27 Million | -28.87% |
| 2024-12-31 | $735.70 Million | -0.54% |
| 2023-12-31 | $739.69 Million | -0.31% |
| 2022-12-31 | $742.01 Million | -2.56% |
| 2021-12-31 | $761.50 Million | +158.98% |
| 2020-12-31 | $294.04 Million | +45.49% |
| 2019-12-31 | $202.10 Million | +9.50% |
| 2018-12-31 | $184.57 Million | +33.94% |
| 2017-12-31 | $137.81 Million | -8.45% |
| 2016-12-31 | $150.52 Million | +15.93% |
| 2015-12-31 | $129.84 Million | +527.23% |
| 2014-12-31 | $20.70 Million | +13.71% |
| 2013-12-31 | $18.20 Million | -12.71% |
| 2012-12-31 | $20.86 Million | +48.41% |
| 2011-12-31 | $14.05 Million | +33.62% |
| 2010-12-31 | $10.52 Million | +44.02% |
| 2009-12-31 | $7.30 Million | +26.02% |
| 2008-12-31 | $5.79 Million | +38.00% |
| 2007-12-31 | $4.20 Million | +36.44% |
| 2006-12-31 | $3.08 Million | +48.31% |
| 2005-12-31 | $2.08 Million | +103.70% |
| 2004-12-31 | $1.02 Million | +16.44% |
| 2003-12-31 | $874.84K | +106.09% |
| 2002-12-31 | $424.49K | +127.96% |
| 2001-12-31 | $186.22K | +48.94% |
| 2000-12-31 | $125.03K | -- |
About NeoGenomics Inc
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to dise… Read more